相关实验视频

Updated: Jan 18, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

CEP55通过MAPK途径促进状黑色素瘤的进展,并预测免疫治疗后的生存率

Meng Cao¹, Rundong Zhang¹, Anlan Hong¹

¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, 210042, China.

Oncology research

|September 8, 2025

概括

中枢体蛋白55kDa (CEP55) 驱动着状黑色素瘤 (AM) 的进展和BRAF抑制剂耐药性. 向CEP55显示了改善AM患者免疫疗法反应的希望.

科学领域:

在瘤学瘤学.
皮肤病学皮肤病学
分子生物学分子生物学

背景情况:

状黑色素瘤 (AM) 是亚洲人群中普遍存在且具有攻击性的皮肤癌亚型.
对于中粒体蛋白55 kDa (CEP55) 在AM病原和治疗反应中的作用,人们的了解有限.

研究的目的:

研究CEP55在状黑色素瘤进展中的作用.
探索CEP55与黑色素瘤患者的临床特征和治疗反应的关联.

主要方法:

在黑色素瘤组织和细胞系中CEP55表达的分析,使用RT-qPCR,西式涂抹和IHC.
对公共数据库 (GEPIA,Sangerbox,TIMER) 的生物信息分析,以确定CEP55与临床数据的相关性.
在体外和体外功能测试,RNA测序和救援实验以阐明机制.
组织微阵列以评估CEP55与免疫检查点的关系.

主要成果:

CEP55过度表达与AM中增加的Breslow厚度和高级TNM阶段相关.
CEP55的敲击抑制了黑色素瘤细胞的增殖,迁移和入侵.
对MAPK信号的CEP55激活赋予了对BRAF抑制剂的抗性.
提高CEP55表达与更好的免疫疗法反应有关.

结论:

CEP55是状黑色素瘤进展的关键因素,并影响免疫治疗结果.
向CEP55代表了提高AM治疗疗效的潜在治疗策略.

关键词:

中心体蛋白55 kDa (CEP55) (CEP55) 是一种中心体蛋白.状黑色素瘤 (AM) 是一种免疫疗法免疫疗法基因激活蛋白激酶 (MAPK) 途径

更多相关视频

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

相关概念视频

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...